24-week

SANUWAVE Announces 24-Week Data From Its Pivotal Trials Investigating the Use of dermaPACE for the Treatment of Diabetic Foot Ulcers

ALPHARETTA, Ga., March 24, 2016 (GLOBE NEWSWIRE) — SANUWAVE Health, Inc.(OTCBB:SNWV) (www.sanuwave.com), today announced positive combined 24-week data from the…